Neuroplast, a Dutch clinical-stage biotech, focusing on cell-based treatments for neurodegenerative diseases, has successfully completed patient inclusion of its Phase II randomized placebo-controlled double-blinded clinical trial to evaluate the effect size of Neuro-Cells® for Traumatic Spinal Cord Injury (TSCI) .
16 patients have been enrolled in a multicenter international, randomized, placebo-controlled, double-blinded Phase II clinical trial Goal: to determine the.
Neuroplast Successfully Completes Patient Inclusion Of Phase Ii Clinical Trial For Traumatic Spinal Cord Injury menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Fast-track status is granted for frontotemporal dementia, next to the existing designation for traumatic spinal cord injury An orphan medicinal product.
Fast-track status is granted for frontotemporal dementia, next to the existing designation for traumatic spinal cord injury An orphan medicinal product designation or orphan disease designation